15-valent recombinant human papillomavirus vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 3, 2024 (NCT06454175)
Timeline
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06756269 | Phase 2 | Jan 15, 2025 | Government of China, Shanghai Bovax Biotechnology Co., Ltd. |
| NCT06454175 | Phase 1 | Aug 3, 2024 | Shanghai Bovax Biotechnology Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Bovax Biotechnology Co., Ltd. | Government | 2 | 2 | 2 | 2024 |
| Government of China | Government | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1